{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:28:36Z","timestamp":1792661316077,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.det.2015.08.012","type":"journal-article","created":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T18:19:11Z","timestamp":1448561951000},"page":"69-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Randomized Controlled Trials for the Treatment of Hidradenitis Suppurativa"],"prefix":"10.1016","volume":"34","author":[{"given":"Dominique C.","family":"van Rappard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan R.","family":"Mekkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thrasivoulos","family":"Tzellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2015.08.012_bib1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0625.2008.00712_1.x","article-title":"What causes hidradenitis suppurativa?","volume":"17","author":"Kurzen","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMcp1014163","article-title":"Clinical practice: hidradenitis suppurativa","volume":"366","author":"Jemec","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2015.08.012_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/derm.2.1.12490","article-title":"Comorbidities of hidradenitis suppurativa (acne inversa)","volume":"2","author":"Fimmel","year":"2010","journal-title":"Dermatoendocrinol"},{"key":"10.1016\/j.det.2015.08.012_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2340\/00015555-1082","article-title":"Psychosocial impact of hidradenitis suppurativa: a qualitative study","volume":"91","author":"Esmann","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2015.08.012_bib5","unstructured":"Miller IM, Hamzawi I. Prevalence, risk factors and co-morbidities of hidradenitis suppurativa. Dermatol Clin, in press."},{"key":"10.1016\/j.det.2015.08.012_bib6","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","article-title":"Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies","volume":"59","author":"Revuz","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/jamadermatol.2014.1165","article-title":"Association of metabolic syndrome and hidradenitis suppurativa","volume":"150","author":"Miller","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib8","series-title":"Dermatologic surgery","first-page":"623","article-title":"Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach","author":"Hurley","year":"1996"},{"key":"10.1016\/j.det.2015.08.012_bib9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib10","unstructured":"Revuz J, Jemec GBE. Diagnosing hidradentitis suppurativa. Dermatol Clin, in press."},{"key":"10.1016\/j.det.2015.08.012_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.det.2015.08.012_bib12","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib13","unstructured":"Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available at: www.cochrane-handbook.org. Accessed March 01, 2015."},{"key":"10.1016\/j.det.2015.08.012_bib14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","article-title":"A\u00a0double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa","volume":"115","author":"Mortimer","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/00042728-200802000-00012","article-title":"Surgical treatment of hidradenitis suppurativa with gentamicin sulfate: a prospective randomized study","volume":"34","author":"Buimer","year":"2008","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.det.2015.08.012_bib18","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jaad.2009.07.048","article-title":"Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser","volume":"62","author":"Mahmoud","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/PRS.0b013e31821e6fb5","article-title":"Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study","volume":"128","author":"Highton","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.det.2015.08.012_bib22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A\u00a0double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.08.012_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/ced.12459","article-title":"New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study","volume":"40","author":"Fadel","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib24","unstructured":"Kimball AB, Jemec GBE, Gu Y, et\u00a0al. A novel hidradenitis suppurativa efficacy variable, HiSCR (Hidradenitis Suppurativa Clinical Response), is responsive to change with adalimumab therapy: results of a phase 2 study. Presented at the 71st Annual Meeting of the American Academy of Dermatology. P6661. Miami Beach, March 1-5, 2013."},{"key":"10.1016\/j.det.2015.08.012_bib25","unstructured":"Horvath B, Mathusiak L. Surgical interventions in hidradentitis suppurativa. Dermatol Clin, in press."},{"key":"10.1016\/j.det.2015.08.012_bib26","unstructured":"Saunte DM, Lapins J. Laser and IPL in hidradentitis suppurativa. Dermatol Clin, in press."},{"key":"10.1016\/j.det.2015.08.012_bib27","unstructured":"Clinical Trial Register of the of the US National Institutes of Health. Available at: http:\/\/clinicaltrials.gov. Accessed March 08, 2015."},{"key":"10.1016\/j.det.2015.08.012_bib28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2230.2001.00876.x","article-title":"Early-onset hidradenitis suppurativa","volume":"26","author":"Palmer","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2015.08.012_bib29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","article-title":"GRADE guidelines: 15. Going from evidence to recommendation\u2013determinants of a recommendation's direction and strength","volume":"66","author":"Andrews","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.det.2015.08.012_bib30","unstructured":"US Food and Drug Administration. Structured approach to benefit-risk assessment in drug regulatory decision-making. Available at: http:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM329758.pdf. Accessed December 16, 2014."}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T07:54:41Z","timestamp":1537170881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863515001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0733863515001084"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2015.08.012","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Controlled Trials for the Treatment of Hidradenitis Suppurativa","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2015.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}